Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 6, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 34,935 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on December 2, 2005, and was advised to the Company on December 5, 2005.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R (1) (b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Key Facts for Investor Verification
- 34,935 Ordinary Shares were transferred from the GSK Trust to employee plan participants on December 2, 2005.
- Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.
- The filing does not contain financial performance data for the period.